




RealRate

PHARMACEUTICAL 2013

AMAG Pharmaceuticals INC
Rank 59 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of AMAG Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AMAG Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 88% points. The greatest weakness of AMAG Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 309%, being 88% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	254,380
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,957
Liabilities, Non-Current	0
Other Assets	460
Other Compr. Net Income	0
Other Expenses	16,435
Other Liabilities	52,383
Other Net Income	-180
Other Revenues	85,378
Property and Equipment	3,297
Research and Development	33,296
Selling, General and Administrative Expense	53,071

Output Variable	Value in 1000 USD
Assets	258,137
Liabilities	85,340
Expenses	102,802
Revenues	85,378
Stockholders Equity	172,797
Net Income	-17,604
Comprehensive Net Income	-17,604
BaseVar	265,918
ECR before LimitedLiability	209%
Economic Capital Ratio	309%